Stonepine Capital Management LLC Grows Holdings in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Stonepine Capital Management LLC increased its stake in ANI Pharmaceuticals by 135.3%, now holding 48,000 shares valued at approximately $3.21 million, making it the firm's 10th largest investment.
• Insider transactions included significant sales by directors, with Jeanne Thoma selling 21,540 shares for about $1.92 million, representing a 47.93% decrease in her position.
• ANI Pharmaceuticals recently reported a quarterly earnings beat with an EPS of $1.80, surpassing estimates and showing a 53.2% year-over-year revenue growth to $211.37 million.

Stonepine Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 135.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 48,000 shares of the specialty pharmaceutical company's stock after buying an additional 27,600 shares during the period. ANI Pharmaceuticals makes up approximately 3.1% of Stonepine Capital Management LLC's holdings, making the stock its 10th biggest holding. Stonepine Capital Management LLC owned 0.22% of ANI Pharmaceuticals worth $3,214,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. National Bank of Canada FI acquired a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $79,000. GAMMA Investing LLC raised its holdings in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the period. Rafferty Asset Management LLC acquired a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $200,000. Bridgefront Capital LLC acquired a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $204,000. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $206,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ANI Pharmaceuticals

In related news, Director Jeanne Thoma sold 21,540 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $89.15, for a total value of $1,920,291.00. Following the completion of the transaction, the director owned 23,405 shares of the company's stock, valued at $2,086,555.75. The trade was a 47.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Matthew J. Leonard sold 2,528 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the transaction, the director owned 6,864 shares in the company, valued at approximately $622,015.68. This represents a 26.92% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 405,538 shares of company stock valued at $35,690,131. 11.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded up $0.23 during mid-day trading on Friday, hitting $92.76. 97,283 shares of the company's stock traded hands, compared to its average volume of 372,422. The firm has a 50 day simple moving average of $72.83 and a two-hundred day simple moving average of $66.78. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $93.72. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -120.47 and a beta of 0.61. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The business had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same quarter last year, the firm posted $1.02 EPS. The company's quarterly revenue was up 53.2% on a year-over-year basis. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 21st. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday, August 11th. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. HC Wainwright reaffirmed a "buy" rating and set a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Finally, Guggenheim reaffirmed a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.